» Articles » PMID: 32460405

FLT3-ITD DNA and MRNA Levels in AML Do Not Correlate with CD7, CD33 and CD123 Expression

Overview
Journal J Cell Mol Med
Date 2020 May 28
PMID 32460405
Citations 3
Authors
Affiliations
Soon will be listed here.
Abstract

Introduction: FLT3 internal tandem duplication (ITD) mutations are found in around 25% of all acute myeloid leukaemia (AML) cases and is associated with shorter disease-free and overall survival. Previous reports have shown that FLT3-ITD induces a specific phenotype in leukemic blasts, which is characterized by high levels of CD33 and CD123, and that expression of CD33 and CD123 is directly influenced by the DNA FLT3-ITD/wild-type FLT3 allelic ratio (AR).

Methods: A total of 42 FLT3-ITD and 104 FLT3-ITD-negative AML patients were analysed. Immunophenotyping data were used to calculate antigen expression levels as the ratio between the geometric mean fluorescence intensities (MFIs) of leukemic blasts and MFIs of negative lymphocyte populations. FLT3-ITD-DNA and RNA analysis was performed, under the same conditions, by capillary electrophoresis.

Results: Compared with the control group, the FLT3-ITD cohort presented significantly higher CD7, CD33 and CD123 levels. In order to assess the impact of FLT3-ITD abundance on antigen expression, the patients were grouped for each parameter into two cohorts using the following threshold values: (a) 0.5 for the AR, according to current AML guidelines; (b) 0.7 for the FLT3-ITD/FLT3-WT mRNA ratio (RR); and (c) 1.3 for the FLT3-ITD RR/AR ratio. We found higher values of CD33 for RR/AR ≥1.3, and no other statistical differences between CD7, CD33 and CD123 levels of the other FLT3-ITD groups. In terms of correlations between MFI values and FLT3-ITD parameters, we only observed a moderate interdependence between CD33 MFI and the RR/AR ratio, and a weak negative correlation between CD123 MFI and AR.

Conclusion: FLT3-ITD mutations induce a specific antigen profile in AML blasts, and our data do not onfirm previous reports of FLT3-ITD AR influencing both CD33 and CD123 expression.

Citing Articles

Single cell proteogenomic sequencing identifies a relapse-fated AML subclone carrying -ITD with CN-LOH at chr13q.

Kim T, Lee H, Capo-Chichi J, Chang M, Yoo Y, Basi G EJHaem. 2022; 3(2):426-433.

PMID: 35846029 PMC: 9175792. DOI: 10.1002/jha2.390.


Mitochondrial Dysfunction and Redox Homeostasis Impairment as Pathomechanisms of Brain Damage in Ethylmalonic Encephalopathy: Insights from Animal and Human Studies.

Grings M, Wajner M, Leipnitz G Cell Mol Neurobiol. 2020; 42(3):565-575.

PMID: 33034777 PMC: 11441250. DOI: 10.1007/s10571-020-00976-2.


FLT3-ITD DNA and mRNA levels in AML do not correlate with CD7, CD33 and CD123 expression.

Soare D, Radu E, Dumitru I, Popov V, Bumbea H, Vladareanu A J Cell Mol Med. 2020; 24(13):7675-7679.

PMID: 32460405 PMC: 7339186. DOI: 10.1111/jcmm.15255.

References
1.
Daver N, Schlenk R, Russell N, Levis M . Targeting FLT3 mutations in AML: review of current knowledge and evidence. Leukemia. 2019; 33(2):299-312. PMC: 6365380. DOI: 10.1038/s41375-018-0357-9. View

2.
Bras A, de Haas V, van Stigt A, Jongen-Lavrencic M, Beverloo H, Te Marvelde J . CD123 expression levels in 846 acute leukemia patients based on standardized immunophenotyping. Cytometry B Clin Cytom. 2018; 96(2):134-142. PMC: 6587863. DOI: 10.1002/cyto.b.21745. View

3.
Haubner S, Perna F, Kohnke T, Schmidt C, Berman S, Augsberger C . Coexpression profile of leukemic stem cell markers for combinatorial targeted therapy in AML. Leukemia. 2018; 33(1):64-74. PMC: 6326956. DOI: 10.1038/s41375-018-0180-3. View

4.
Ehninger A, Kramer M, Rollig C, Thiede C, Bornhauser M, von Bonin M . Distribution and levels of cell surface expression of CD33 and CD123 in acute myeloid leukemia. Blood Cancer J. 2014; 4:e218. PMC: 4080210. DOI: 10.1038/bcj.2014.39. View

5.
Soare D, Radu E, Dumitru I, Popov V, Bumbea H, Vladareanu A . FLT3-ITD DNA and mRNA levels in AML do not correlate with CD7, CD33 and CD123 expression. J Cell Mol Med. 2020; 24(13):7675-7679. PMC: 7339186. DOI: 10.1111/jcmm.15255. View